Subscribe
Webinars
White Papers
Buyer's Guide
PhotonicsNXT
Get Published!
Lasers/Sources
Detectors/Imaging
Optics
Bio & Life Sciences
Laser Processing
Test/Measurement
Science & Research
Recent Quotes
View Full List
My Watchlist
Create Watchlist
Indicators
DJI
Nasdaq Composite
SPX
Gold
Crude Oil
BioOptics Stock Watch
Markets
Stocks
ETFs
Tools
Overview
News
Currencies
International
Treasuries
Amgen
(NQ:
AMGN
)
326.78
-2.02 (-0.61%)
Streaming Delayed Price
Updated: 4:00 PM EDT, Aug 26, 2024
Add to My Watchlist
Quote
Overview
Detailed Quote
Charting
Historical Prices
News
All News
News Headlines
Press Releases
Research
Quarterly Reports
Insider Filings
Other Filings
All News about Amgen
< Previous
1
2
...
5
6
7
8
9
10
11
12
13
...
44
45
Next >
3 Fantastic Dow Stocks to Buy in February 2024
February 05, 2024
The venerable index is more representative of today's economy and these three Dow stocks to buy are brightly shining component stars.
Via
InvestorPlace
Topics
Economy
Stocks
Exposures
Economy
US Equities
NVO, LLY or AZN: Which Pharma Stock Is the Best Weight-Loss Investment?
February 05, 2024
The relaunch of Wegovy last year caused a mad dash by weight loss stocks to compete for market leadership in anti-obesity drugs.
Via
InvestorPlace
Amgen Is Trying To Take On Lilly, Novo In Obesity Treatment — Here's Why Lilly Stock Just Hit A Record
February 05, 2024
Amgen is looking to rival Eli Lilly and Novo Nordisk in weight-loss drugs.
Via
Investor's Business Daily
Weight Loss Drug's New Entrant: Amgen To Compete With Novo Nordisk, Eli Lilly, As Investigational Weight Loss Drug Shows Encouraging Early Data
February 05, 2024
Amgen's AMG 133 data. Promising results in obesity drug trials, including significant weight loss and improved metabolic markers.
Via
Benzinga
Preview: Amgen's Earnings
February 05, 2024
Via
Benzinga
Is Amgen Stock a Buy Now?
February 01, 2024
The biotech has an excellent track record, but that isn't enough to make its shares attractive.
Via
The Motley Fool
Amgen Options Trading: A Deep Dive into Market Sentiment
January 30, 2024
Via
Benzinga
Expert Outlook: Amgen Through The Eyes Of 11 Analysts
January 29, 2024
Via
Benzinga
Is Amgen a Good Dividend Stock to Buy Right Now?
January 29, 2024
Its diverse product mix and strong fundamentals make a decent case.
Via
The Motley Fool
IBM, Verizon, Merck stocks lead Dow to new highs
January 31, 2024
The Dow hits record highs with IBM, Verizon, Merck, and insurer Travelers leading the way; those strong stocks don't make much of a dent in S&P performance
Via
MarketBeat
Topics
Stocks
Exposures
US Equities
Amgen's Planning to Take a Bite Out of Cancer. Here's What It Means for the Stock.
January 27, 2024
Its new approach to treating cancer is more than just a nibble around the edges.
Via
The Motley Fool
Should You Buy the Dogs of the Dow in 2024?
January 27, 2024
The popular dividend-investing strategy has been around for years. Is it right for you?
Via
The Motley Fool
Topics
Stocks
Exposures
US Equities
P/E Ratio Insights for Amgen
January 26, 2024
Via
Benzinga
5 top healthcare stocks for earnings growth in 2024
January 25, 2024
2024 holds promise for healthcare stocks, with Humana, Elevance, and others expected to boost earnings, as analysts say many industry pressures have been removed.
Via
MarketBeat
Amgen Options Trading: A Deep Dive into Market Sentiment
January 17, 2024
Via
Benzinga
Why NASDAQ:AMGN is a Top Pick for Dividend Investors.
January 12, 2024
Balancing Dividends and Fundamentals: The Case of AMGEN INC (NASDAQ:AMGN).
Via
Chartmill
ABBV: This Top Biotech Just Went On A Buying Spree
January 25, 2024
AbbVie stock is a buy following its recent merger & acquisition activity (Immunogen and Cerevel).
Via
Talk Markets
Stocks to Watch: 3 Companies Working on Next-Gen Weight Loss Drugs
January 25, 2024
The best weight-loss drug stocks firms improving the drugs or developing new, potentially superior weight-loss treatments.
Via
InvestorPlace
What's Going On Johnson & Johnson Stock Today?
January 24, 2024
JNJ reports strong earnings, beats expectations for Q4 of 2023, with increased sales and successful acquisitions. Stock closes lower, settles talc litigation, and delays competitor's launch.
Via
Benzinga
Topics
Earnings
Exposures
Financial
This 1 Bullish Move by Merck Could Drive Growth for Years to Come
January 23, 2024
It's buying a company with sophisticated biotechnology platforms that could drive lots of growth -- eventually.
Via
The Motley Fool
5 Magnificent Dividend Growth Stocks to Buy and Hold Forever
January 23, 2024
These dividend growers ought to shine in 2024 and beyond.
Via
The Motley Fool
Amgen's Blockbuster Osteoporosis Drug Prolia Flagged With FDA Strictest Warning
January 19, 2024
FDA issues serious warning on Amgen's Prolia drug, highlighting increased risk of low calcium levels in specific patient groups.
Via
Benzinga
Exposures
Product Safety
Dividend Income Update December 2023
January 17, 2024
The beginning of every month is exciting for all dividend income investors as we look back at the previous month and see how much passive dividend income our portfolios generated.
Via
Talk Markets
Cathie Wood's Ark Invest Liquidates $15.8M Worth Of ProShares Bitcoin Strategy ETF Units
January 16, 2024
On Tuesday, Cathie Wood-led Ark Invest made a significant move by selling $15.84 million worth of ProShares Bitcoin Strategy ETF (NYSE:BITO) units.
Via
Benzinga
Topics
ETFs
Stocks Struggle As U.S. Dollar Sees Safety Bid
January 16, 2024
Once again, we are seeing stocks struggle whenever the dollar catches a bid. But not all hope is lost for bulls, as various semiconductor stocks continue to hold up well.
Via
Talk Markets
10 Health Care Stocks With Whale Alerts In Today's Session
January 15, 2024
Via
Benzinga
5 Biotech Stocks That Could Be Big Winners in 2024 and Beyond
January 15, 2024
These five biotech companies could have a lot of room to run.
Via
The Motley Fool
Why Vera Therapeutics Stock Soared by 22% This Week
January 12, 2024
Executive changes and a bullish analyst take combined to boost sentiment on the company.
Via
The Motley Fool
Large Drugmakers Show Enthusiasm To Embrace $100B Obesity Market, Despite Novo And Lilly's Dominance
January 11, 2024
Pharmaceutical companies, including Amgen Inc (NASDAQ: AMGN) and Pfizer Inc (NYSE: PFE), are strategically positioning themselves to tap into the
Via
Benzinga
AbbVie's Strategic Move: ImmunoGen Acquisition Triggers Golden Cross, Yet Valuation Caution Remains
January 11, 2024
AbbVie Inc (ABBV) stock is up 15% since acquiring ImmunoGen, but past Golden Cross rallies haven't sustained. With high valuation and competition, investors may want to wait for a pullback.
Via
Benzinga
< Previous
1
2
...
5
6
7
8
9
10
11
12
13
...
44
45
Next >
Data & News supplied by
www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy
and
Terms and Conditions
.